HEALTHJun 30 · 12:25 UTCWSOC ABC CHARLOTTENatalie Dreier, Cox Media Group National Content Desk

Medicare to cover GLP-1 treatments for weight loss

Medicare will cover GLP-1 weight-loss treatments through a temporary pilot program starting July 1, allowing eligible participants to pay a $50 monthly co-pay. The program includes Eli Lilly’s Zepbound and Foundayo and Novo Nordisk’s Wegovy, with coverage ending by 2027 due to federal law restrictions. Eligibility requires a BMI of 35 or higher (or 30 with specific health conditions), and prior authorization is needed.

Nexus surfaces and summarizes. The full story lives at the source.

Mentioned

MedicareorganizationEli LillyorganizationNovo NordiskorganizationZepboundtopicFoundayotopicWegovytopicGLP-1 treatmentstopicPresident Donald Trump’s administrationorganization

Spot something wrong with this article?Report a problem →

Forward this

Related Signal

Adjacent reporting

HEALTHMay 6 · 09:00 UTC
A New Medicare Option for Weight Loss Drugs: What Older Americans Should Know
HEALTHJun 29 · 17:11 UTC
Medicare will start covering weight-loss drugs on July 1 for the first time
HEALTHJun 1 · 08:30 UTC
STAT+: Medicare still won’t say how much covering obesity drugs will cost
HEALTHJun 29 · 11:50 UTC
Medicare is starting to cover weight loss drugs for some seniors — here's what to know